When new treatments for cancer are submitted for review, the pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. If you are eligible to take one of our surveys, you can have your voice included in this important submission process. We also periodically provide surveys that help us define our future policy initiatives.
See below for our current survey opportunities to see if you are eligible.
CCSN Prostate Cancer Survey
The purpose of this survey is to help the prostate cancer community and the Canadian Cancer Survivor Network better understand the journey that prostate cancer patients, survivors and caregivers experience during their transition from diagnosis, through to treatment, follow-up, and survivorship.
By participating in this survey, you will be helping us to shape messages for its upcoming advocacy efforts, aimed at improving the quality of life of prostate cancer patients, and advocate for a better continuum of care and journey for Canadians facing a prostate cancer diagnosis.
This survey takes about fifteen minutes to complete and will close in March 2019.
Patient Input: Lenvatinib (Lenvima) for unresectable hepatocellular carcinoma (HCC)
This survey is to gather insights and perspectives about living with and managing liver cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for unresectable hepatocellular carcinoma called Lenvatinib (Lenvima).
At this time we are primarily looking for patients with hepatocellular carcinoma (primary liver cancer) and their caregivers who would be interested in participating in this survey. If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.
This survey takes about ten minutes to complete and will close on February 14th, 2019.
Patient Input: Larotrectinib for TRK Gene Fusion Positive Cancers
This survey is to gather insights and perspectives from patients and caregivers who are managing TRK gene fusion–positive cancers. This is in order to complete a patient evidence submission for a new medication for TRK gene fusion–positive cancers called Larotrectinib.
For this survey, we are only looking for input from patients with TRK gene fusion–positive cancer and their caregivers at this time. In the survey, you will be asked to further specify your cancer type and your role (patient/caregiver). Please answer the questions carefully.
This survey takes about fifteen minutes to complete and will close on February 22nd, 2019.